A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor

Summary

This is a Phase 1 open-label, dose-escalation, safety and pharmacokinetic study of rucaparib administered twice daily (BID) to Japanese patients with a solid tumor who have failed previous standard treatment for their cancer. A recommended dose of rucaparib for Japanese patients will be determined in a dose-escalation portion and then further evaluated in a dose-expansion portion of the study.

Timeline

Start

2018-02-06

Primary completion

2019-06-18

Completion

2022-04-13

Drugs

Indications